In September 2026 Eli Lilly patented longer-acting treatments for diabetes, obesity, fatty liver disease, and related metabolic conditions.
Abstract
Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.
What this signalsA new patent often shows where a company is putting its R&D budget.
Tags
Technologies named
patents-companypatentGrantGet every patent signal for Eli Lilly and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Eli Lilly this week?”
The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/3e640197-8920-589f-a97c-6bc0c69b5601 returns this record as JSON. POST /v1/companies/enrich returns every signal for lilly.com.
{
"signal_id": "3e640197-8920-589f-a97c-6bc0c69b5601",
"signal_type": "patents-company",
"signal_subtype": "patentGrant",
"detected_at": "2026-09-23T14:50:59+00:00",
"company": {
"name": "Eli Lilly",
"domain": "lilly.com"
},
"data": {
"cpc": [
{
"code": "C07K 14/605"
},
{
"code": "A61K 38/00"
}
],
"tags": [
"Intellectual Property",
"Research & Development",
"Pharmaceuticals",
"Medical Research"
],
"detail": "In September 2026 Eli Lilly patented longer-acting treatments for diabetes, obesity, fatty liver disease, and related metabolic conditions.",
"summary": "Eli Lilly was granted a patent for multi-receptor incretin medicines.",
"event_at": "2026-09-22",
"inventors": [
{
"name": "Jorge Alsina-Fernandez",
"status": "unresolved",
"is_primary": true
},
{
"name": "Tamer Coskun",
"status": "resolved",
"is_primary": false,
"linkedin_url": "https://www.linkedin.com/in/tamer-coskun-39359817"
},
{
"name": "Lili Guo",
"status": "resolved",
"is_primary": false,
"linkedin_url": "https://www.linkedin.com/in/lili-guo-79505623"
},
{
"name": "Hongchang Qu",
"status": "resolved",
"is_primary": false,
"linkedin_url": "https://www.linkedin.com/in/hongchang"
}
],
"event_kind": "grant_date",
"grant_date": "2026-09-22",
"source_url": "https://patents.google.com/patent/US12741999",
"cpc_primary": {
"code": "C07K 14/605"
},
"patent_title": "Incretin analogs and uses thereof",
"patent_number": "US12741999",
"uspto_assignee": "ELI LILLY AND COMPANY",
"patent_abstract": "Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.",
"precision_class": "structural",
"invention_explanation": "Engineered hormone-like molecules that activate GIP, GLP-1, and glucagon receptors in a balanced way and remain active in the body longer.",
"technologies_mentioned": [
"incretin analogs",
"peptide therapeutics",
"metabolic disease treatment"
]
}
}
curl https://signals.autobound.ai/v1/signals/3e640197-8920-589f-a97c-6bc0c69b5601 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"lilly.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.